Plate 4(克隆），NR-1_Vaccinia virus

NR-19525?? Salmonella enterica subsp. enterica, Strain Ty2 (Serovar Typhi), Gateway? Clone Set, Recombinant in Escherichia coli, Plate 4(Clones)|Salmonella enterica subsp. enterica|Salmonella enterica subsp. enterica, Strain Ty2 (Serovar Typhi), Gateway? Clone Set, Recombinant in Escherichia coli, Plate 4|-80°C or colder|Pathogen Functional Genomics Resource Center at the J. Craig Venter InstituteAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Salmonella enterica subsp. enterica, Strain Ty2 (Serovar Typhi), Gateway^? Clone Set, Recombinant in Escherichia coli, Plate 4, NR-19525."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.The Salmonella enterica subsp. enterica (S. enterica subsp. enterica), strain Ty2 (serovar Typhi), Gateway^? clone set consists of approximately 3380 sequence validated clones from S. enterica subsp. enterica, strain Ty2, cloned in Escherichia coli (E. coli) DH10B-T1 cells. Each open reading frame was constructed in vector pDONR?221 (Invitrogen?) with an ATG start codon and no stop codon. The sequence was validated by full length sequencing of each clone with greater than 1X coverage and a mutation rate of less than 0.2%.Information related to the use of Gateway^? Clones can be obtained from Invitrogen?. Recombination was facilitated through an attB substrate (attB-PCR product or a linearized attB expression clone) with an attP substrate (pDONR?221) to create an attL-containing entry clone. The entry clone contains recombinational cloning sites, attL1 and attL2 to facilitate gene transfer into a destination vector, M13 forward and reverse priming sites for sequencing and a kanamycin resistance gene for selection. Please refer to the Invitrogen? Gateway^? Technology Manual for additional details.Plate orientation and viability were confirmed for NR-19525.Each inoculated well of the 96-well plate contains approximately 60 ?L of E. coli culture (strain DH10B-T1) in Luria Bertani (LB) broth containing 50 ?g/mL kanamycin supplemented with 15% glycerol.Clone plates are replicated using a BioMek^? FX robot. Production in the 96-well format has increased risk of cross-contamination between adjacent wells. Individual clones should be purified (e.g. single colony isolation and purification using good microbiological practices) and sequence-verified prior to use. BEI Resources only confirms the clone plate orientation and viability of randomly picked clones. BEI Resources does not confirm or validate individual clone identities provided by the contributor.

NR-19480?? Helicobacter pylori Gateway? Clone Set, Recombinant in Escherichia coli, Plate 4(Clones)|Helicobacter pylori|Helicobacter pylori Gateway? Clone Set, Recombinant in Escherichia coli, Plate 4|-80°C or colder|Pathogen Functional Genomics Resource Center at the J. Craig Venter InstituteAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Helicobacter pylori Gateway^? Clone Set, Recombinant in Escherichia coli, Plate 4, NR-19480."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.The Helicobacter pylori (H. pylori) Gateway^? clone set consists of approximately 1600 sequence validated clones from H. pylori, strain 26695 and strain J99 cloned in Escherichia coli (E. coli) DH10B-T1 cells. Each open reading frame was constructed in vector pDONR?221 (Invitrogen?) with an ATG start codon and no stop codon. The sequence was validated by full length sequencing of each clone with greater than 1X coverage and a mutation rate of less than 0.2%.Information related to the use of Gateway^? Clones can be obtained from Invitrogen?. Recombination was facilitated through an attB substrate (attB-PCR product or a linearized attB expression clone) with an attP substrate (pDONR?221) to create an attL-containing entry clone. The entry clone contains recombinational cloning sites, attL1 and attL2 to facilitate gene transfer into a destination vector, M13 forward and reverse priming sites for sequencing and a kanamycin resistance gene for selection. Please refer to the Invitrogen? Gateway^? Technology Manual for additional details.Each inoculated well of the 96-well plate contains approximately 60 ?L of E. coli culture (strain DH10B-T1) in Luria Bertani (LB) Broth containing 50 ?g/mL kanamycin supplemented with 15% glycerol.Note: Production in the 96-well format has increased risk of cross-contamination between adjacent wells. Individual clones should be purified (e.g. single colony isolation and purification using good microbiological practices) and sequence-verified prior to use. BEI Resources cannot confirm or validate any clone not identified on the plate information table found on the Product Information Sheet.